Table 5.
Treatment Outcomes of Small Cell Lung Carcinoma/ Neuroendocrine Tumor Patients With Brain Metastases Treated With SRS
| Study | Year | No. of patients* / lesions | Median No. of brain metastases (range) | Sequence of SRS | Median dose (Gy) | 1-year LRFS | 1-year DBRFS | MS after SRS | ||
|---|---|---|---|---|---|---|---|---|---|---|
| After PCI | After WBRT | Upfront | ||||||||
| Primary small cell lung carcinoma | ||||||||||
| Serizawa33 | 2002 | 34 (total 245) | 4.6 (1–10) | — | — | 100% | 21 | 94.5% | — | 9.1 mo |
| Wegner34 | 2011 | 44 / 128 | 1 (1–14) | 27.3% | 54.5% | 18.2% | 18 | 86% | 39% | 9 mo |
| Jo30 | 2011 | 50 / 202 | 4 (1–15) | 22% | 54% | 24% | 17.4 | 70.3% | 70.3% | 6.3 mo |
| Harris29 | 2012 | 51 | 2–4 (1–5) | 31.4% | 68.6% | — | 18 | 57% | 42% | 5.9 mo |
| Olson18 | 2012 | 27 | 2 (1–6) | 30% | 70% | — | 20.5 | 76.5% | 40% | 3 mo |
| Grandhi38 | 2012 | 5 (total 61) | 13.2 (10–28) | — | 75.4% | 24.6% | 16 | 58.3% | 22.4% | 4 mo |
| Kuremsky31 | 2013 | 31 / 271 | 2 | 83.9% | — | 16.1% | 20 | 54% | 37% | 5.9 mo |
| Nakazaki32 | 2013 | 44 / 473 | 5 (1–36) | 22.7% | 77.3% | — | 20 | 96.4% | 42.9% | 5.8 mo |
| Yomo35 | 2014 | 41 / 121 | 2 (1–10) | — | — | 100% | 20 | 86% | 56% | 8.1 mo |
| Yomo36 | 2015 | 70 / 292 | 2 (1–21) | 10% | 22.9% | 67.1% | 20 | 77% | 53% | 7.8 mo |
| Primary small cell carcinoma of cervix | ||||||||||
| Chung39 | 2013 | 3 (total 13) | 5.7 (1–16) | — | 33.3% | 66.7% | 14 | 66.7% | 77.8% | 4.6 mo |
| Mixed patient population | ||||||||||
| Our study | 2015 | 33 / 147 | 3 (1–24) | 33.3% | 36.4% | 30.3% | 20 | 82.5% | 29.3% | 6.9 mo |
Abbreviation: DBRFS, distant-brain recurrence-free survival; LRFS, local recurrence-free survival; MS, median survival; PCI, prophylactic cranial irradiation; SRS, stereotactic radiosurgery; WBRT, whole brain radiation therapy.
* Number of patients with small cell carcinoma/total number of patients in study.